Inclusion Criteria:

- Diagnosis of CML in chronic phase.

- ECOG <2.

- Normal organ function and ULN Total bili, AST and ALT.

- Must have the ability to understand and sign a written consent form

Exclusion Criteria:

- Patients may not be receiving any other investigational agents.

- May not have prior treatment with Imatinib, Dasatinib, Nilotinib or other tyrosine
kinase inhibitors.

- Patients must not have uncontrolled intercurrent illness including, but not limited
to, ongoing or active infections, symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmias, or psychiatric illness/social situations that
would limit compliance with study requirements.

- Pregnant or nursing mothers

- Patients must have no prior malignancies except for; adequately treated non-melanoma
skin cancer, cervical carcinoma-in-situ, adequately treated Stage I or II cancer from
which the patient is in complete remission, or any other cancer from which the
patient has been disease free for 5 years